Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wolff

Showing results (791-800 of 831) with videos related to

Pageof 84
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2019
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 TrialHyman B Muss, Mei-Yin C Polley, Donald A Berry, et al.
The Lancet. Oncology|March 1, 2023
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trialSara M Tolaney, Paolo Tarantino, Noah Graham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP Tarantino, G Viale, M F Press, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
DNA Methylation Markers for Breast Cancer Detection in the Developing WorldBradley M Downs, Claudia Mercado-Rodriguez, Ashley Cimino-Mathews, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2024
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022R A Freedman, H M Heiling, T Li, et al.
Archives of Pathology & Laboratory Medicine|June 8, 2010
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerM Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, et al.
Journal of the National Cancer Institute|May 1, 2019
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Tomás Pascual, Carmine De Angelis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 10, 2012
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelinesRobert W Carlson, D Craig Allred, Benjamin O Anderson, et al.
Journal of Medicinal Chemistry|February 9, 2024
Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel WarheadN G R Dayan Elshan, Karen C Wolff, Laura Riva, et al.
Archives of Pathology & Laboratory Medicine|July 1, 2010
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, et al.
Pageof 84

Showing results (791-800 of 831) with videos related to

Sort By:
Pageof 84
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2019
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 TrialHyman B Muss, Mei-Yin C Polley, Donald A Berry, et al.
The Lancet. Oncology|March 1, 2023
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trialSara M Tolaney, Paolo Tarantino, Noah Graham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP Tarantino, G Viale, M F Press, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
DNA Methylation Markers for Breast Cancer Detection in the Developing WorldBradley M Downs, Claudia Mercado-Rodriguez, Ashley Cimino-Mathews, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2024
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022R A Freedman, H M Heiling, T Li, et al.
Archives of Pathology & Laboratory Medicine|June 8, 2010
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerM Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, et al.
Journal of the National Cancer Institute|May 1, 2019
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Tomás Pascual, Carmine De Angelis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 10, 2012
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelinesRobert W Carlson, D Craig Allred, Benjamin O Anderson, et al.
Journal of Medicinal Chemistry|February 9, 2024
Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel WarheadN G R Dayan Elshan, Karen C Wolff, Laura Riva, et al.
Archives of Pathology & Laboratory Medicine|July 1, 2010
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, et al.
Pageof 84